

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**REQUEST FOR FILING NATIONAL PHASE OF**  
**PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495**

To: Hon. Commissioner of Patents  
Washington, D.C. 20231

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: P 0280624 /1998-30-0526WO  
M# /Client Ref.

From: Pillsbury Winthrop LLP, IP Group:

Date: May 23, 2001

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

- |  |  |  |
|--|--|--|
| 1. International Application<br><br><u>PCT/US99/27654</u><br><u>↑ country code</u> | 2. International Filing Date<br><br><u>23 November 1999</u><br>Day <u>MONTH</u> Year | 3. Earliest Priority Date Claimed<br><br><u>23 November 1998</u><br>Day <u>MONTH</u> Year<br>(use item 2 if no earlier priority) |
|--|--|--|
4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

(a) ☐ 20 months from above item 3 date      (b) ☒ 30 months from above item 3 date,

(c) Therefore, the due date (unextendable) is May 23, 2001

Title of Invention TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

Inventor(s) Marco A. Coccia

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

☒ Please immediately start national examination procedures (35 U.S.C. 371 (f)).

☒ **A copy of the International Application** as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:

- a. ☒ Request;  
b. ☒ Abstract;  
c. 31 pgs. Spec. and Claims;  
d. 2 sheet(s) Drawing which are ☐ informal ☒ formal of size ☒ A4 ☐ 11"

9. ☒ **A copy of the International Application has been transmitted by the International Bureau.**

10. **A translation of the International Application** into English (35 U.S.C. 371(c)(2))

- a. ☐ is transmitted herewith including: (1) ☐ Request; (2) ☐ Abstract;  
(3) \_\_\_\_\_ pgs. Spec. and Claims;  
(4) \_\_\_\_\_ sheet(s) Drawing which are:  
☐ informal ☐ formal of size ☐ A4 ☐ 11"
- b. ☒ is not required, as the application was filed in English.  
c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.  
d. ☐ Translation verification attached (not required now).

11. ☒ **PLEASE AMEND** the specification before its first line by inserting as a separate paragraph:

- a. ☒ --This application is the national phase of international application PCT/US99/27654 filed November 23, 1999 which designated the U.S, and that international application ☒ was ☐ was not published under PCT Article 21(2) in English.--  
b. ☒ --This application also claims the benefit of U.S. Provisional Application No. 60/ 109,607, filed November 23, 1998 --

9. \_\_\_\_\_ (No.) Certified copy (copies): ☐ attached; ☐ previously filed (date) \_\_\_\_\_  
 in U.S. Application No. \_\_\_\_\_ / \_\_\_\_\_ filed on \_\_\_\_\_
10. Small Entity Status ☐ ☒ is Not claimed ☐ is claimed (file PAT-256 if this is the first claim of Small Entity Status)
11. ☐ Attached:
12. ☐ Preliminary Amendment:

**THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED**

				Large/Small Entity		Fee Code
13. Basic Filing Fee .....				Design Application	\$320/\$160	106/26
				Not Design Application	\$710/\$355	101/201
14. Total Effective Claims		minus 20 =		x \$18/\$9	+0	103/203
15. Independent Claims		minus 3 =		x \$80/\$40	+0	102/202
16. If <u>any proper</u> multiple dependent claim (ignore improper) is present, (Leave this line blank if this is a reissue application)					\$270/\$135	104/204
17. Surcharge for filing Declaration/filing fee late					\$130/\$65	105/205
18. <b>FILING FEE ENCLOSED =</b>					<b>\$130</b>	
19. <b>Original due date:</b> August 3, 2001						
20. <b>Petition is hereby made</b> to extend the <u>original</u> due date to				(1 mo)	\$110/\$55 =	115/215
cover the date this response is filed for which the requisite fee				(2mos)	\$390/\$195 =	116/216
is attached				(3mos)	\$890/\$445 =	117/217
				(4mos)	\$1390/\$695 =	118/218
21. If "non-English" box 3 is X'd, add Rule 17(k) processing fee .....					\$130	+0
22. If "assignment" box 5 is X'd, add recording fee. ....					\$40	+40
23. Petition Fee for					\$130	+0
24. <b>TOTAL FEE ENCLOSED =</b>					<b>\$280</b>	

Our Deposit Account No. 03-3975

Our Order No. 037003

C#

0280624

M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. **This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.**

09/06/2001 LLANDGRA 00000069 09856534

01 FC:154

130.00 DP

02 FC:115

110.00 DP

**Pillsbury Winthrop LLP**  
**Intellectual Property Group**

1600 Tysons Boulevard

By Atty: Robin L. Teskin

Reg. No. 35,030

McLean, VA 22102

Sig: *Robin L. Teskin*

Fax: (703) 905-2500

Tel: (703) 905-2000

Tel: (703) 905-2200

Atty/Sec: RLT/LAK

**NOTE: File in duplicate with PTO receipt (PAT-103A) and attachments**

RE: USA National Filing of PCT /US99/27654

JC18 Rec'd PCT/PTO 23 MAY 2001

12. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:
13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. ☐ Translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of claim amendments made before 18th month, is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
- a. ☐ is submitted herewith ☐ Original ☐ Facsimile/Copy
- b. ☒ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**
- a. Was prepared by ☐ European Patent Office ☐ Japanese Patent Office ☒ Other
- b. ☒ has been transmitted by the international Bureau to PTO.
- c. ☒ copy herewith (2 pg(s).) ☐ plus Annex of family members (\_\_\_ pg(s).).
17. **International Preliminary Examination Report (IPER):**
- a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
- b. ☒ copy herewith in English.
- c.1 ☐ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
- c.2 ☐ Specification/claim pages # \_\_\_ claims # \_\_\_  
Dwg Sheets # \_\_\_
- d. ☐ Translation of Annex(es) to IPER (required by 30<sup>th</sup> month due date, or else annexed amendments will be considered canceled).
18. **Information Disclosure Statement** including:
- a. ☐ Attached Form PTO-1449 listing documents
- b. ☐ Attached copies of documents listed on Form PTO-1449
- c. ☒ A concise explanation of relevance of ISR references is given in the ISR.
19. ☐ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. ☐ Copy of Power to IA agent.
21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): \_\_\_ sheet(s) per set: ☐ 1 set informal;  
☐ Formal of size ☐ A4 ☐ 11"
22. Small Entity Status ☐ is **Not** claimed ☐ is claimed (pre-filing confirmation required)
- 22(a) \_\_\_ (No.) Small Entity Statement(s) enclosed (since 9/8/00 Small Entity Statement(s) not essential to make claim)
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) United States of:
- |     | <u>Application No.</u> | <u>Filing Date</u> |     | <u>Application No.</u> | <u>Filing Date</u> |
|-----|------------------------|--------------------|-----|------------------------|--------------------|
| (1) | 60/109,607             | 23 November 1998   | (2) | _____                  | _____              |
| (3) | _____                  | _____              | (4) | _____                  | _____              |
| (5) | _____                  | _____              | (6) | _____                  | _____              |
- a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
- b. ☒ Copy of Form PCT/IB/304 attached.
24. Attached:

RE: USA National Filing of PCT/US99/27654

JC18 Rec'd PCT/PTO 23 MAY 2001

## 25. Preliminary Amendment:

25.5 Per Item 17.c2, cancel original pages #\_\_\_\_, claims #\_\_\_\_, Drawing Sheets #

## 26. Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:

Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☐ 17, ☐ 25, ☐ 25.5 (hilit)

Total Effective Claims	26	minus 20 =	6	x \$18/\$9	=	\$108	966/967
Independent Claims	2	minus 3 =	0	x \$80/\$40	=	\$0	964/965
If any proper (ignore improper) Multiple Dependent claim is present,				add \$270/\$135	+	0	968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ BASIC FEE REQUIRED, NOW →→→→

A. If country code letters in item 1 are not "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

See item 16 re:

1. Search Report was <u>not prepared</u> by EPO or JPO	-----	add \$1000/\$500		960/961
2. Search Report was prepared by EPO or JPO	-----	add \$860/\$430	+0	970/971

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL", "NZ", "IN" or "ZA"

→ <input type="checkbox"/> B.	If USPTO did not issue <u>both</u> International Search Report (ISR) <u>and</u> (if box 4(b) above is X'd) the International Examination Report (IPER),	-----	add \$1000/\$500	+0	960/961
→ <input type="checkbox"/> C.	If USPTO issued ISR but not IPER (or box 4(a) above is X'd),	-----	add \$710/\$355	+0	958/959
→ <input checked="" type="checkbox"/> D.	If USPTO issued IPER but IPER Sec. V boxes <u>not all</u> 3 YES,	-----	add \$690/\$345	+690	956/957
→ <input type="checkbox"/> E.	If international preliminary examination fee was paid to USPTO <u>and</u> Rules 492(a)(4) and 496(b) <u>satisfied</u> (IPER Sec. V <u>all</u> 3 boxes YES for <u>all</u> claims),	-----	add \$100/\$50	+0	962/963

SUBTOTAL = \$798

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ----\$40 +0 (581)

29. Attached is a check to cover the ----- TOTAL FEES \$798

Our Deposit Account No. 03-3975

Our Order No. 037003

C#

0280624


M#

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filedPillsbury Winthrop LLP  
Intellectual Property Group1100 New York Avenue, NW  
Ninth Floor  
Washington, DC 20005-3918  
Tel: (202) 861-3000  
Atty/Sec: RLT/kmh

By Atty: Robin L. Teskin

Sig:



Reg. No. 35,030

Fax: (202) 822-0944  
Tel: (202) 861-3623NOTE: File in duplicate with 2 postcard receipts (PAT-103) & attachments.

-1-

TUMOR ANTIGEN-SPECIFIC  
ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

BACKGROUND OF THE INVENTION

**Field of the Invention**

5           The present invention relates to novel chimeric proteins which comprise a tumor antigen-specific monoclonal antibody or some fragment thereof at the amino terminus fused to an immunostimulatory ligand at the carboxyl terminus. Such chimeric proteins serve to enhance anti-tumor immune responses at the site of the tumor by stimulating endogenous leukocytes which express receptor for the immunostimulatory ligand portion of the chimeric protein on their cell surface.

**Technology Background**

          All publications and patent applications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

15           One important factor in the development of successful antitumor agents is the ability to design agents that will selectively kill tumor cells, while exerting relatively little, if any, harmful effects against normal tissues. This goal has been elusive to achieve, though, in that there are few qualitative differences between neoplastic and normal tissues. Because of this, much research over the years has focused on identifying tumor-specific "marker antigens" that can serve as immunological targets both for chemotherapy and diagnosis.

          Many tumor-specific, or quasi-tumor-specific ("tumor-associated"), markers have been identified as tumor cell antigens that can be recognized by specific antibodies. Tumor-associated antigens (TAAs) are also expressed on normal cells to varying degrees, generally during different stages of

-2-

differentiation. Therefore, these antigens are also known as "differentiation antigens" (*Fundamental Immunology*, 3<sup>rd</sup> edition, W. Paul, ed., Raven Press, New York, 1993, Ch. 32). Despite the fact that TAAs are also expressed on normal cells to some extent, studies suggest that differences in expression levels between  
5 normal and malignant cells can often be enough to favor a therapeutic response (Oettgen, H.F. and Old, L.J., *The History of Cancer Immunotherapy*; DeVita et al. eds.; *Biologic Therapy of Cancer*, Lippincott, Philadelphia, 1991, pp. 87-119).

A variety of tumor-associated antigens (TAA) have been described as summarized in U.S. Patent No. 5,766,588, herein incorporated by reference in its  
10 entirety. In addition, assays for identifying tumor associated antigens and tumor specific antigens are known in the art, as described in U.S. Patent No. 5,763,164, also incorporated by reference in its entirety. Identification of tumor-specific and tumor-associated antigens will enable the identification and isolation of monoclonal antibodies specific for these antigens using well-established  
15 techniques in the art. However, it is generally the case that tumor specific antibodies will not in and of themselves exert sufficient antitumor effects to make them useful in cancer immunotherapy. Indeed, despite the variety of tumor-associated antigens which have now been identified, tumor cells remain poorly immunogenic.

20 Recently there has been a great deal of activity directed toward augmenting the immune response to tumor-associated antigens. These strategies attempt to alter the local immunological environment of the tumor cell so as to enhance the presentation of T-cell epitopes or to enhance the activation of tumor-specific T-lymphocytes (Pardoll, D., *Immunol. Today*, 14:310-316 [1993]). Such strategies  
25 have included: coinjection of tumor cells with adjuvants (Bartlett et al., 1972, *J. Natl. Cancer Inst.*, 48:245-257); "heterogenization" of tumor cells by infection

-3-

with viruses (Austin and Boone, 1979, *Adv. Cancer Res.*, 30: 301-345), by hapten conjugation (Mitchison, 1970, *Transplant Proc.*, 2: 92-103) or exposure to mutagens (Van Pel and Boon, 1982, *Proc. Natl. Acad. Sci USA*, 79: 4718-4722); transfection of tumor cells to express the B7 ligand to provide a costimulatory  
5 signal to T cells (Chen et al., 1992, *Cell*, 71: 1093-1102); and transfection of tumor cells to produce certain cytokines.

For instance, several cytokine genes have been introduced into tumor cells to produce vaccines having varying degrees of effect on both tumorigenicity and immunogenicity. Tumor cells have been modified with genes for interleukin-2 (IL-  
10 2) (Porgador, A., et al., *Int. J. Cancer*, 53:471-477 [1993]); interferon-alpha, (IFN-alpha)(Porgador, A., et al., *Int. Immunol.*, 150:1458-1570 [1993]); granulocyte-macrophage colony stimulating factor (GM-CSF) (Dranoff, G., et al., *Proc. Nat. Acad. Sci. USA*, 90:3539-3543 [1993]) and several others (see Paul's *Fundamental Immunology*, 3<sup>rd</sup> edition, p. 1158).

15 Attempts have also been made to modify expression of the MHC complex in order to improve the immunogenicity of tumor cells. Enhanced expression of MHC class I antigens following exposure of cells to cytokines or transfection of cells with genes specifying MHC class I antigens has been shown to render the treated cells more susceptible to lysis by CTLs (Weber, J. S., et al., *Cancer Res.*,  
20 48:5818 [1988]); Zoller, M., *Int. J. Cancer*, 41:256 [1988]); Porgador, A., et al., *J. Immunogenet.*, 16:291 [1989]).

However, while the above approaches may have been shown to have some success in experimental models for some types of cancer, no general approach has been identified that enhances immune responses toward tumor cells in general.  
25 This may be due to the observation that, while most tumor cells can be shown to express some tumor-specific or tumor-associated antigens, the different

-4-

components of humoral and cell-mediated immunity react differently to and play different roles in the various types of cancer and tumor disease models (for a review, see Paul's *Fundamental Immunology*, 3<sup>rd</sup> ed., pp. 1158-1165).

For instance, some tumor cells are killed *in vitro* by a process involving antibody coating, opsonization and either phagocytosis by macrophages or antibody-dependent cell-mediated cytotoxicity in the presence of macrophages, natural killer cells or neutrophils. For some tumor cells, TNF produced by macrophages has been shown to be responsible for the cytotoxic effects observed *in vitro* (Urban et al. 1986, *Proc. Natl. Acad. Sci USA*, 83: 5233-5237).

Corresponding effects *in vivo*, however, have not been readily achieved.

However, in rare instances, dramatic therapeutic effects have been achieved when cancer patients were treated with murine monoclonal antibodies (Houghton et al., 1985, *Proc. Natl. Acad. Sci. USA*, 82: 1242-1246; Goodman et al., 1990, *J. Clin. Oncol.*, 8: 1083). In addition, *in vivo* studies have suggested a role for NK cells in reducing metastatic dissemination of injected cancer cells (Talmadge et al., 1980, *J. Natl. Cancer Inst.*, 65: 801-809; Hanna et al., 1981, *J. Immunol.*, 127: 1754-1758). Moreover, there is some evidence that activation of macrophages *in vivo* plays a role in reducing metastasis in some experimental models (Whitworth et al., 1990, *Cancer Metastasis Review*, 4: 319-351).

For other types of tumors, i.e., virally- (LeClerc et al., 1973, *Int. J. Cancer*, 11: 426-432) and chemically-induced tumors (Rouse et al., 1972, *Nature New Biol.*, 238: 116-117), the requirement for T-cell mediated immunity has been clearly demonstrated. For example, in a model of MCA-induced tumors in mice, it was shown that transfer of immune cells but not of immune sera could transfer systemic tumor-specific immunity into irradiated mice (Old et al., 1962, *Ann. N.Y. Acad. Sci.*, 101: 80-106). Yet for other tumors, i.e., UV-induced tumors, CD8+



-5-

cytolytic T cells are required for tumor rejection. In fact, for these tumors, elimination of CD4+ T cells has even been shown to increase tumor rejection (Koeppen et al., 1993, *Transplant.*, 55).

Thus, it appears that different immune effector cells have varying degrees of relevance in the immune response to any particular type of tumor. For cellular cytolytic responses, analyses of effector cell phenotype, specificity and mechanism of action have shown that even a response against a single type of tumor cell can be multiclonal, mediated by multiple mechanisms, and/or directed against different determinants expressed on the same tumor cells (Anichini et al., 1987, *Immunol. Today*, 8: 385-389; North, 1984, *Contemp. Top. Immunobiol.*, 13: 243-257). Therefore, strategies which are aimed at enhancing systemic immunity via antigen-specific stimulation at the site of the tumor may be more universally applicable to a wider array of cancers than has been demonstrated for the various cancer therapeutic strategies reported thus far.

The immune system is capable of producing two types of antigen-specific responses to foreign antigens. Cell-mediated immunity is the term used to refer to effector functions of the immune system mediated by T lymphocytes. Humoral immunity is the term used to refer to production of antigen-specific antibodies by B lymphocytes. It has long been appreciated that the development of humoral immunity against most antigens requires not only antibody-producing B lymphocytes but also the involvement of helper T (hereinafter Th) lymphocytes. (Mitchison, *Eur. J. Immunol.*, 1:18-25 (1971); Claman and Chaperon, *Transplant Rev.*, 1:92-119 (1969); Katz et al., *Proc. Natl. Acad. Sci. USA*, 70:2624-2629 (1973); Raff et al., *Nature*, 226:1257-1260 (1970)).

While some B lymphocyte help is mediated by soluble molecules released by Th cells (for instance lymphokines such as IL-4 and IL-5), activation of B cells

-6-

also requires a contact-dependent interaction between B cells and Th cells. (Hirohata et al., *J. Immunol.*, 140:3736-3744 (1988); Bartlett et al., *J. Immunol.*, 143:1745-1765 (1989)). This indicates that B cell activation involves an obligatory interaction between cell surface molecules on B cells and Th cells.

5 Such an interaction is further supported by the observation that isolated plasma membranes of activated T cells can provide helper functions necessary for B cell activation. (Brian, *Proc. Natl. Acad. Sci. USA*, 85:564-568 (1988); Hodgkin et al., *J. Immunol.*, 145:2025-2034 (1990); Noelle et al., *J. Immunol.*, 146:1118-1124 (1991)).

10 The process by which T cells help B cells to differentiate has been divided into two distinct phases; the inductive and effector phases (Vitetta et al., *Adv. Immunol.*, 45:1 (1989); Noelle et al., *Immunol. Today*, 11:361 (1990)). Although the inductive phase of T cell help is Ag-dependent and MHC-restricted (Janeway et al., *Immun. Rev.*, 101:34 (1988); Katz et al., *Proc. Natl. Acad. Sci., USA*, 15 10:2624 (1973); Zinkernagle, *Adv. Exp. Med. Biol.*, 66:527 (1976)); the effector phase of T cell helper function can be Ag-independent and MHC-nonrestricted (Clement et al., *J. Immunol.*, 132:740 (1984); Hirohata et al., *J. Immunol.*, 140:3736 (1988); Whalen et al., *J. Immunol.*, 143:1715 (1988)).

Although terminal B cell differentiation requires both contact- and

20 lymphokine-mediated stimuli from T cells, intermediate stages of B cell differentiation can be induced by activated T cell surfaces in the absence of secreted factors (Crow et al., *J. Exp. Med.*, 164:1760 (1986); Brian, *Proc. Natl. Acad. Sci., USA*, 85:564 (1988); Sekita et al., *Eur. J. Immunol.*, 18:1405 (1988); Hodgkin et al., *J. Immunol.*, 145:2025 (1990); Noelle et al., *FASEB J*, 5:2770

25 (1991)). These intermediate effects on B cells include induction of surface CD23 expression (Crow et al., *Cell Immunol.*, 121:94 (1989)), enzymes associated with

-7-

cell cycle progression (Pollok et al., *J. Immunol.*, 146:1633 (1991)) and responsiveness to lymphokines (Noelle et al., *FASEB J.*, 5:2770 (1989); Pollok et al., *J. Immunol.*, 146:1633 (1991)).

Recently some of the activation-induced T cell surface molecules and the  
5 corresponding ligands on the surface of B cells that are involved in B cell  
activation have been identified. A cell surface molecule, CD40, has been  
identified on immature and mature B lymphocytes which, when crosslinked by  
antibodies, induces B cell proliferation. Valle et al., *Eur. J. Immunol.*, 19:1463-  
1467 (1989); Gordon et al., *J. Immunol.*, 140:1425-1430 (1988); Gruder et al., *J.*  
10 *Immunol.*, 142:4144-4152 (1989).

CD40 has been molecularly cloned and characterized (Stamenkovic et al.,  
*EMBO J.*, 8:1403-1410 (1989)). CD40 is expressed on B cells, interdigitating  
dendritic cells, macrophages, follicular dendritic cells, and thymic epithelium  
(Clark, *Tissue Antigens* 36:33 (1990); Alderson et al., *J. Exp. Med.*, 178:669  
15 (1993); Galy et al., *J. Immunol.* 142:772 (1992)). Human CD40 is a type I  
membrane protein of 50 kDa and belongs to the nerve growth factor receptor  
family (Hollenbaugh et al., *Immunol. Rev.*, 138:23 (1994)). Signaling through  
CD40 in the presence of IL-10 induces IgA, IgM and IgG production, indicating  
that isotype switching is regulated through these interactions. The interaction  
20 between CD40 and its ligand results in a primed state of the B cell, rendering it  
receptive to subsequent signals.

Also, a ligand for CD40, gp39 (also called CD40 ligand or CD40L) has  
recently been molecularly cloned and characterized (Armitage et al., *Nature*,  
357:80-82 (1992); Lederman et al., *J. Exp. Med.*, 175:1091-1101 (1992);  
25 Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992)). The gp39 protein is  
expressed on activated, but not resting, CD4<sup>+</sup> Th cells. Spriggs et al., *J. Exp. Med.*,

-8-

176:1543-1550 (1992); Lane et al., *Eur. J. Immunol.*, 22:2573-2578 (1992); and Roy et al., *J. Immunol.*, 151:1-14 (1993). Cells transfected with gp39 gene and expressing the gp39 protein on their surface can trigger B cell proliferation and, together with other stimulatory signals, can induce antibody production. Armitage et al., *Nature*, 357:80-82 (1992); and Hollenbaugh et al., *EMBO J.*, 11:4313-4319 (1992). The gp39 ligand has been identified for the mouse (Noelle et al., *Proc. Natl. Acad. Sci. USA*, 89:6550 (1992); Armitage et al., *Nature*, 357:80 (1992)) and for humans (Hollenbaugh et al., *Embo. J.* 11:4313 (1992); Spriggs et al., *J. Exp. Met.*, 176:1543 (1992)). gp39 is a type II membrane protein and is part of a new gene super family which includes TNF- $\alpha$ , TNF- $\beta$  and the ligands for FAS, CD27, CD30 and 4-1BB. gp39<sup>+</sup> T cells produce IL-2, IL-4 and IFN- $\gamma$  (Van der Eetwegh et al., *J. Exp. Med.*, 178:1555 (1993)).

Unique insights into the novel role of gp39 in the regulation of humoral immunity have been provided by studies of a human disease, X-linked hyper-IgM syndrome (HIM). HIM is a profound, X-linked immunodeficiency typified by a loss in thymus dependent humoral immunity, the inability to produce IgG, IgA and IgE. Mutations in the gp39 gene were responsible for the expression of a non-functional gp39 protein and the inability of the helper T cells from HIM patients to activate B cells (Allen et al., *Science*, 259:990 (1993); Aruffo et al., *Cell*, 72:291 (1993); DiSanto et al., *Nature*, 361:541 (1993); Korthauer et al., *Nature*, 361:539 (1993)). These studies support the conclusion that early after T cell receptor engagement of the peptide/MHC class II complex, gp39 is induced on the cognate helper T cell, and the binding of gp39 to CD40 on the B cell induces the B cell to move into the cell cycle and differentiate to immunoglobulin (Ig) secretion and isotype switching.

-9-

Functional studies have shown that treatment of mice with anti-gp39 completely abolished the antibody response against thymus dependent antigens (SRBC and TNP-KLH), but not thymus independent antigens (TNP-Ficoll) (Foy et al., *J. Exp. Med.*, 178:1567 (1993)). In addition, anti-gp39 has been shown to prevent formation of memory B cells and germinal centers in mouse spleen (Foy et al., *J. Exp. Med.*, 180:157 (1994)). Moreover, CD40 ligation has also been shown to play an important role in IL2-R expression, IL-12 production and B7.1 expression by activated B cells (Nishioka and Lipsky, 1994, *J. Immunol.* 153: 1027). Collectively, these data provide extensive evidence that the interaction between gp39 on T cells and CD40 on B cells is essential for antibody responses against thymus dependent antigens.

CD40 ligation on dendritic cells (DC) stimulates IL-12 production (Koch et al., 1996, *J. Exp. Med.* 184(2):741-746) and enhances surface expression of ICAM-1 and B7.1 (Cella et al., 1996, *J. Exp. Med.* 184(2):747-752), all of which are important contributors to Th1-type, CTL-mediated immune responses (Heufler et al., 1996, *Eur. J. Immunol.*, 26:659). Thus, gp39-CD40 interaction appears to play a role in both cell-mediated immunity and antibody-specific immune responses, and is likely to enhance tumor specific responses in cancers which respond to either cell-mediated or humoral immune mechanisms.

The prediction that the gp39-CD40 interaction may be manipulated for therapeutic approaches to cancer is supported by two recent publications. First, Grossman et al. showed that transgenic expression of gp39 on neuroblastoma cells generated a significant reduction in tumor growth, even when only 1.5% of the tumor cells expressed gp39 ( $p < 0.001$ ) (*Human Gene Therapy*, 1997, 8(16): 1935-1943). In addition, the anti-tumor effects protected the mice from subsequent challenge by parental tumor cells, indicating that the responses were due to

-10-

systemic immunomodulation that once initiated, were gp39-independent. Second, Kato et al. showed that transfection of gp39 into chronic lymphocytic leukemia B cells induced autologous immune recognition and antileukemia immune response (*J. Clin. Invest.*, 1998, 101(5): 1144-1151).

5           However, one disadvantage in applying these reported strategies in the commercial setting, as well as in many of the strategies discussed above, is that cancer cells must be isolated from each individual patient and transfected with a gp39 construct in order to ensure proper cell compatibility in the subsequent immune response. Alternatively, one could attempt gene therapy techniques to  
10   target the gp39 construct to cancer cells, but such techniques have not been developed to the point where they are universally applicable to any type of cell on a predictable basis. In light of the forgoing, there remains a need for cancer therapeutic agents which enhance immune responses against targeted tumor-specific or tumor-associated antigens without the need for *ex vivo* cell  
15   modification or gene targeting techniques.

          The present invention addresses the deficiencies of the prior art by providing chimeric protein constructs which contain a tumor antigen-specific antibody binding domain (or TAA-specific antibody) fused to the CD40 binding domain of the gp39 ligand. Such chimeric proteins provide effective and  
20   convenient therapeutic reagents which will enhance immune responses toward a wide variety of cancers for which a tumor-specific or tumor-associated antigen may be identified.

          Chimeric proteins containing an antibody component fused to other types of molecules have previously been described and are known in the art. Antibody  
25   fusions have been generated to deliver cells, cytotoxins, or drugs to specific sites. An important use has been to deliver host cytotoxic cells, such as natural killer or

-11-

cytotoxic T cells, to specific cellular targets. (Staerz et al., *Nature*, 314:628 (1985); Songilvilai, et al., *Clin. Exp. Immunol.*, 79:315 (1990)). Another important use has been to deliver cytotoxic proteins to specific cellular targets. (Raso et al., *Cancer Res.*, 41:2073 (1981); Honda et al., *Cytotechnology*, 4:59 (1990)). A further  
5 important use has been to deliver anti-cancer non-protein drugs to specific cellular targets (Corvalan et al., *Intl. J. Cancer Suppl.*, 2:22 (1988); Pimm et al., *Brit. J. Can.*, 61:508 (1990)).

Antibodies have also been fused to toxic molecules for the purpose of delivering them specifically to cancer cells. For instance, U.S. Patent No.  
10 5,756,699, herein incorporated by reference in its entirety, provides a thorough review of the state of art concerning immunotoxins, whereby the variable region of an antibody gene is fused to the gene for a bacterial toxin. It was hoped that such reagents could be used to target tumor cells, however, such fusion proteins have been shown to be immunogenic and toxic in animals.

15 Challida et al. disclose a B7.1-antibody fusion protein specific for the tumor-associated antigen HER2/*neu*. However, in contrast to the recombinant DNA constructs of the present invention, the construct disclosed in Challida et al. fuses the gene for the B7.1 ligand at the 5' end of the antibody nucleic acid such that the ligand is fused to the amino terminus of the antibody. This is an awkward  
20 position for the ligand portion of the chimeric protein as it has the potential to interfere with antigen binding by the antibody binding pocket. Moreover, the goal of the Challida reference was to stimulate T cells specifically, while the goal of the present invention is to provide an enhanced systemic immune response for the treatment of a wide variety of cancers.

25 U.S. Patent No. 5,767,260, also incorporated by reference herein in its entirety, discloses an immunoeffector-antibody fusion protein comprising a tumor

-12-

antigen-specific antibody fused to Phospholipase A activating protein ("PLAP"). PLAP is a protein that activates phospholipase A, a lipolytic enzyme which hydrolyzes the 2-acyl fatty acid ester of glycerophospholipids. This hydrolysis releases arachidonic acid which is converted into a number of biologically active compounds called eicosanoids. PLAP has been postulated to be involved in the inflammatory cascade in certain biological settings, and induces eicosanoid release and stimulation of joint inflammation, related to rheumatoid arthritis.

The ability of Fc receptors to trigger activation of phospholipase A<sub>2</sub> led to the finding that inhibitors of phospholipase A<sub>2</sub> could apparently inhibit phagocytosis by macrophages of IgG-coated particles (Lennartz et al., 1991, *J. Immunol.*, 147: 621-626). Conversely, the exogenous addition of arachidonic acid restores phagocytic capabilities. Thus, the goal of U.S. Patent No. 5,767,260 is to stimulate phagocytic activity at the region of tumors, in contrast to the present invention, which seeks to stimulate a systemic immune response.

In addition, the role of phospholipase A<sub>2</sub> in Fc receptor signaling is far from clear, and has been the subject of some debate due to studies which demonstrated that the block of arachidonic acid release in certain assay systems has not inhibited the phagocytosis of IgG-coated erythrocytes (Yamada et al., 1989, 142: 2457-2463). Moreover, even if PLAP-antibody fusion proteins are able to enhance phagocytosis at the site of some tumors, the extensive research summarized above indicates that phagocytosis alone will not be effective for all types of cancer.

Clearly, there remains a need in the art for therapeutic, immunomodulatory reagents which may be employed for the treatment of a wide variety of diseases by virtue of their ability to stimulate a systemic immune response.



-13-

### SUMMARY OF THE INVENTION

The present invention pertains to dual function chimeric proteins comprising both an antigen binding domain and a receptor ligand binding domain, wherein said receptor ligand is involved in immune cell modulation and stimulation. Such proteins may be constructed by linking or bonding together two protein or protein fragments, or may be synthesized from recombinant DNA constructs as fusion proteins.

Preferably the chimeric proteins of the present invention are synthesized from recombinant DNA constructs. In general, such a construct comprises a nucleic acid encoding at least a heavy chain variable region binding domain of a disease antigen-specific antibody fused to a nucleic acid encoding at least a binding portion of an immunostimulatory ligand such that expression of said nucleic acid molecule yields a fusion protein having the heavy chain antibody variable region domain at its amino terminus and the binding portion of the immunostimulatory ligand at its carboxyl terminus. When expressed in a host cell with the corresponding light chain of the particular disease antigen-specific antibody, a chimeric protein is formed comprising at the very least an Fv fragment of the antibody fused to the binding domain of an immunostimulatory ligand.

A nucleic acid molecule according to the present invention may also comprise a nucleic acid encoding at least one antibody constant region. A construct with one heavy chain constant region will result in a fusion protein wherein the binding portion of the immunostimulatory ligand is fused to a Fab fragment of the disease antigen-specific antibody. A construct with at least part of the second constant region of the antibody will include sequences encoding the cysteine residue involved in heavy chain disulfide bridge formation, and will result in a fusion protein wherein the binding portion of the immunostimulatory ligand

-14-

is fused to an F(ab')<sub>2</sub> fragment of the disease antigen-specific antibody (See Figure 1). Fusion proteins comprising full length antibody proteins are also included.

A nucleic acid molecule according to the present invention may also comprise a nucleic acid encoding a light chain antibody or antibody fragment  
5 fused with said nucleic acid encoding said antibody variable region. In such a construct, the nucleic acid encoding said light chain antibody or antibody fragment is typically fused to said nucleic acid encoding said antibody variable region at the 5' end in such a way that upon expression, the light chain and heavy chain variable regions associate to form an antigen binding pocket (See Figure 1D). Proper  
10 association and folding of the two antibody fragments typically requires a flexible peptide linker, which is encoded by a nucleic acid present between the light chain and heavy chain coding regions in the nucleic acid construct.

The chimeric proteins of the present invention are specifically designed to enhance immune responses by cells of the immune system in the vicinity of  
15 diseased cells by providing a dual function binding protein that binds to both an antigen on the surface of the diseased cell and to a receptor on the surface of an immune cell. The diseased cell antigen may be a tumor antigen or a viral antigen, or any antigen that is specifically expressed on the particular cells targeted for enhanced immune responses.

20 The immune cell receptor may be any receptor specifically expressed on immune cells, but is preferably one which stimulates immune cell responses upon ligand interaction, such as cytokine production, costimulatory molecule expression, APC function or T helper cell stimulation. In particular, the immunostimulatory ligand is a CD40 ligand, and is most preferably gp39 or the  
25 receptor binding portion thereof.

-15-

The two binding portions of the dual function chimeric protein may optionally be connected by a linker peptide of variable length, which is encoded by an additional, in-frame coding region in the nucleic acid constructs of the present invention. The necessity of such a linker peptide will depend on the nature of the targeted antigen, i.e., its location and accessibility, the receptor for the immunostimulatory ligand, and the particular constraints of tertiary protein structure for each particular immunostimulatory ligand and antigen binding domain.

The present invention also encompasses chimeric proteins encoded by the nucleic acid constructs described above, as well as chimeric proteins that can be constructed by binding together the two separate protein domains, i.e., using bifunctional chelators or other linking proteins. Pharmaceutical compositions comprising the chimeric proteins of the present invention in a pharmaceutically acceptable carrier are also included. It has been demonstrated by Shopes (*J. Immunol.*, 148(9):2918-2922, 1992) that "tail-to-tail" dimeric IgG-IgG dimers having tetravalent binding could be generated through the formation of a disulfide linkage between individual heavy chains on the Ig molecule. A similar approach was used by Caron et al (*J. Exp. Med.*, 176:1191-1195, 1992). Both groups used a genetically engineered approach to artificially introduce a cysteine four amino acids from the carboxyl end of the heavy chain (position 444). Tetravalent IgG/IgG dimers were also developed using chemical approaches (Ghetie et al, *PNAS*, 94:7509-7514, 1997) in which a thioether linkage was generated between the IgG molecules. Unfortunately, in the Ghetie approach, the chemical cross-linking was random and not limited to a specific site on the IgG heavy chain.

The present invention also includes vectors and host cells comprising the nucleic acid molecules described above. Host cells may be prokaryotic or

-16-

eukaryotic depending on the purpose for expressing the vector. For instance, prokaryotic cells will be more convenient for multiplying, isolating and maintaining vectors comprising the nucleic acid, whereas eukaryotic cells may be required for expression and isolation of properly folded and active protein depending on the antigen binding and ligand binding domains chosen for the nucleic acid construct. Host cells may also contain the nucleic acids of the present invention integrated into the chromosome. Any type of vector may be used depending upon the particular host cell chosen for expression of the nucleic acid, including prokaryotic and eukaryotic vectors, viral or phage vectors, etc.

Host cells which express the chimeric proteins of the present invention may be used in a method of making the chimeric proteins comprising expressing the nucleic acid molecule of the invention in a host cell and isolating the resulting chimeric protein. The particular method of protein purification will depend upon the particular expression system used as well as the nature of the chimeric protein. For instance, chimeric proteins having an antigen binding domain may be isolated and purified using columns made from the target antigen. Alternatively, purification columns may be designed using the immune cell receptor which interacts with the ligand binding domain. Classical methods of protein purification including DSFF or CM chromatography may also be used depending on the physical properties of the chimeric protein. Such techniques are well known in the art.

The chimeric proteins of the present invention may be used in a method of enhancing disease antigen-specific antibody responses in a subject who expresses the relevant disease antigen. Such a method comprises administering the chimeric protein of the invention to such a subject such that disease antigen-specific or systemic immune responses, i.e., cytokine production, costimulatory molecule

-17-

expression, APC function, helper and cytotoxic T cell stimulation, etc., are enhanced. Such enhanced immune response may also provide a method of treating a disease in a patient in need of such treatment, where such treatment may prevent, alleviate or cure the particular disease. Diseases which particularly  
5 benefit from the method of the present invention include cancer and viral infections such as AIDS.

It is anticipated that the present invention will have particular use in hospital or outpatient settings. Accordingly, kits comprising the chimeric proteins in sterile form whereby the proteins may be easily administered to a patient are  
10 also encompassed in the present invention. For the laboratory setting where those of skill in the art might wish to purchase the vectors of the present invention for the purpose of modifying the vectors with alternative binding domains, kits comprising the nucleic acid molecules, vectors and appropriate host cells are also included. Columns for purifying the resulting chimeric protein may also be  
15 included.

Other aspects and variations of the present invention will become clear in the drawings and description to follow.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1. Diagrammatic representation of proposed chimeric TAA-specific  
20 mAb/gp39 immunotherapeutic fusion proteins and their corresponding DNAs.

Figure 2. A diagrammatic representation of the anti-tumor immune response generated by a TAA specific monoclonal antibody-gp39 chimeric protein construct.

-18-

**DETAILED DESCRIPTION OF THE INVENTION****Definitions**

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined.

A “nucleic acid molecule” may be DNA or RNA, and may contain modified nucleotide bases so long as such modified bases do not inhibit expression of the encoded chimeric protein.

A “heavy chain variable region binding domain” is the most minimal portion of an antibody heavy chain variable region capable of association with the corresponding light chain of the antibody and subsequent antibody recognition.

A “disease antigen” may be any antigen specifically expressed by, or shown to be preferentially associated with, a diseased cell. A “diseased cell” may be a tumor, cancer, or malignant cell, or a virally-infected cell. A tumor antigen may be tumor-specific, i.e., only expressed by tumor cells, or tumor-associated (TAA), i.e., also expressed by normal cells but perhaps at a different time or at a different level. A disease antigen for the purposes of the present invention must be expressed on the surface of a diseased cell, either by virtue of its own secretory signals, or in context with an MHC molecule. A disease antigen may also be expressed on the surface of a phagocytic cell, i.e., a macrophage, following phagocytosis, for instance in context with an MHC molecule.

An “antibody” according to the present invention may be from any species so long as it is specific for the targeted antigen. The antibody may be derived

-19-

from a humanized antibody or other antibody gene which has been genetically engineered. The "antibody" may be an antibody fragment, i.e., an Fv, FAB, F(ab') or F(ab)<sub>2</sub> fragment, the structure of all of which are known in the art as described in U.S. Patent No. 5,648,237, herein incorporated by reference.

5        When referring to nucleic acids, the term "fused" means that the two nucleic acids are fused in such a way that a single protein molecule or peptide chain is formed upon expression of the fused nucleic acid construct.

         A "binding portion of an immunostimulatory ligand" means the minimal region of any ligand which interacts with or binds to the immunostimulatory  
10    receptor molecule which is targeted by the chimeric protein of the present invention. An "immunostimulatory receptor molecule" is any receptor on the surface of an immune cell, the ligation or binding of which stimulates an immune response from the cell on which it is expressed. For instance, when the targeted immunostimulatory receptor is CD40, the immunostimulatory ligand is any  
15    molecule which interacts with and binds to CD40, i.e., a CD40 monoclonal antibody or fragment thereof, gp39, or any other molecule which is demonstrated to bind specifically or particularly to CD40.

         A "fusion protein" is a chimeric protein resulting from expression of a nucleic acid sequence which encodes peptide sequences derived or designed from  
20    more than one native protein sequence. The term "derived" indicates the sequences were designed from the native protein sequence, but may contain amino acid substitutions which do not inhibit, or perhaps even increase, the stability or functional capabilities of the chimeric protein. Such amino acid substitutions may be a necessary result of nucleotide base changes required for the formation of  
25    restriction endonuclease cleavage sites during construction of the recombinant DNA construct.

-20-

A nucleic acid encoding a "compatible" antibody light chain or light chain fragment contains a variable region domain which, upon expression, contributes to the formation of the antigen binding pocket. This nucleic acid molecule may be fused in frame to the N terminus of the heavy chain recombinant DNA construct by a sequence of nucleotides which encode a flexible peptide linker. This flexible peptide linker is designed with an appropriate length and sequence such that the light chain and heavy chain regions of the antibody may take on the native conformation of the antigen binding pocket.

A "subject who expresses a disease antigen" or a "patient" may be either human or animal. A patient may be "in need of treatment" without actually demonstrating physical symptoms of disease so long as the patient expresses the disease antigen on a diseased cell. The term "treatment" encompasses any therapeutic regimen where the aim is to prevent, alleviate or cure the particular disease, and may be accomplished if the disease progression is merely slowed or symptoms are alleviated for any period of time no matter how brief.

"Disease antigen-specific responses" may include cytokine production, costimulatory molecule expression, APC function, T helper cell stimulation, the infiltration of immune cells to the site of the diseased antigen or cell, such as, infiltration by T cells, B cells, macrophages and other lymphocytes. The immunostimulatory moieties in the fusion molecules of the invention can also cause or modulate, for example, the activation of lymphocyte cells, the expression of lymphocyte-specific compounds, the elaboration of antibodies, the enhancement of phagocytosis by phagocytes, and the enhancement of tumor cell lysis, or any immune cell response which is a specific result of the binding or ligation of the target immunostimulatory receptor.



-21-

The variable regions of both heavy and light chains show considerable variability in structure and amino acid composition from one antibody molecule to another, whereas the constant regions show little variability. The term "variable" as used in this specification refers to the diverse nature of the amino acid sequences of the antibody heavy and light chain variable regions. Each antibody recognizes and binds antigen through the binding site defined by the association of the heavy and light chain variable regions into an F[V] area. The light-chain variable region V[L] and the heavy-chain variable region V[H] of a particular antibody molecule have specific amino acid sequences that allow the antigen-binding site to assume a conformation that binds to the antigen epitope recognized by that particular antibody.

Within the variable regions are found regions in which the amino acid sequence is extremely variable from one antibody to another. Three of these so-called "hypervariable" regions or "complementarity-determining regions" (CDR's) are found in each of the light and heavy chains. The three CDR's from a light chain and the three CDR's from a corresponding heavy chain form the antigen-binding site.

### **The Chimeric Protein Construct**

It is preferred that the chimeric proteins of the invention be constructed according to one of the following basic forms. The first form comprises an antigen binding, i.e., the variable region from an antibody heavy chain fused at its C terminus to an immunoeffector protein moiety. The protein may optionally contain a peptide spacer between the two functional domains, so that the structure will generally be: NH<sub>2</sub>-V[H]-immunoeffector moiety-COOH or NH<sub>2</sub>-V[H]-spacer-immunoeffector moiety-COOH. The construct may optionally contain the variable region from the corresponding light chain antibody fused to the N-

-22-

terminus, preferably by a flexible peptide linker, such that the basic form will generally be: NH<sub>2</sub>-V[L]-spacer-V[H]-immunoeffector moiety-COOH. The protein may also comprise constant region domains from both the light and heavy chains of the antibody, such that varying portions of a single chain antibody are fused to the N-terminus of the immunostimulatory ligand (See Figure 1).

Processes for creating single chain antibody fusions wherein a light chain variable region is fused to a heavy chain variable region are disclosed in U.S. Patent No. 5,767, 260, herein incorporated by reference. A computer-assisted method for designing a linker to bridge the variable domains is described more particularly in U.S. Pat. No. 4,704,692, also incorporated by reference in its entirety. A description of the theory and production of single-chain antigen-binding proteins is found in U.S. Pat. Nos. 4,946,778 and 5,260,203. Such single-chain antigen-binding proteins have been shown to have binding specificity and affinity substantially similar to that of the corresponding Fab fragment.

Linkers used in the fusion constructs of the invention can be any of those linkers known or used in the art. Skilled artisans will be able to determine the appropriate linker to be used for a particular construct. It is preferred that the linkers utilized in constructing the antigen-binding fusion proteins of the invention are between 0 and 50 amino acids in length.

In some cases it may be necessary to separate the antigen-binding part of a fusion protein from the immunoeffector part of the fusion protein by a peptide spacer, in order to preserve both activities of the fusion protein. It is also preferred that the spacers are between 0 and 50 amino acids in length.

U.S. Patent No. 5,648,237, herein incorporated by reference in its entirety, provides a thorough description of the various antibody fragments which result by including varying degrees of the antibody constant region. For instance, the term

-23-

Fv is defined to be a covalently or noncovalently-associated heavy and light chain heterodimer which does not contain constant domains. The term Fab' may be defined as a polypeptide comprising a heterodimer of the variable domain and the first constant domain of an antibody heavy chain, plus the variable domain and  
5 constant domain of an antibody light chain, plus at least one additional amino acid residue at the carboxyl terminus of the heavy chain C[H]1 domain including one or more cysteine residues. F(ab')<sub>2</sub> antibody fragments are pairs of Fab' antibody fragments which are linked by a covalent bond(s). The Fab' heavy chain may include a hinge region. This may be any desired hinge amino acid sequence.  
10 Alternatively the hinge may be entirely omitted in favor of a single cysteine residue or, preferably a short (about 1-10 residues) cysteine-containing polypeptide. In certain applications, a common naturally occurring antibody hinge sequence (cysteine followed by two prolines and then another cysteine) is used; this sequence is found in the hinge of human IgG1 molecules (E. A. Kabat, et al.,  
15 *Sequences of Proteins of Immunological Interest*, 3rd edition (National Institutes of Health, Bethesda, Md., 1987)). The hinge region may also be selected from another desired antibody class or isotype.

Depending on the animal used to develop antibodies toward the target disease antigen, the antibody portion of the chimeric protein may generate an anti-  
20 antibody response in the subject receiving the chimeric protein. To alleviate this immune response, antibodies may be "humanized" (i.e., if the subject is a human). A humanized antibody is generally understood to be an immunoglobulin amino acid sequence variant or fragment thereof which is capable of binding to a predetermined antigen and which comprises a FR (framework) region having  
25 substantially the amino acid sequence of a human immunoglobulin and a CDR

-24-

having substantially the amino acid sequence of a non-human immunoglobulin or a sequence engineered to bind to a preselected antigen.

Methods for identifying and immunizing with the target antigen and methods for the identification and isolation of monoclonal antibody-producing hybridomas specific for the target antigen are well-known techniques in the art, as is isolating cDNA fragments which encode the relevant light and heavy chain antibody fragments for further manipulation and cloning. A useful laboratory manual for such general techniques is Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor New York, but a wide variety of other reference materials are readily accessible.

The chimeric protein constructs of the present invention comprise an immunostimulatory ligand binding domain. A preferred immunostimulatory ligand is gp39, which has been shown to bind to CD40 on the surface of antigen presenting cells and thereby enhance immune responses.

The chimeric proteins of the present invention may contain any portion of gp39 or other immunostimulatory ligand so long as that portion is capable of interacting with or binding to its cognate receptor, and the chimeric protein as a whole is able to effectuate an immune response stemming from ligation of this cognate receptor. Such binding portions may be identified using any assay known in the art for measuring the binding capabilities or affinities of peptide fragments of a ligand to the corresponding receptor. For instance, peptide fragments may be synthesized according to the known sequence of gp39, and used in a competitive binding assay with gp39+ T cells. Alternatively, peptide display libraries may be generated using techniques known in the art and screened for the capability to bind CD40+ cells. The entire extracellular portion of the gp39 molecule may also be used. In addition, the immunoeffector domain may lack ligand binding activity

-25-

individually so long as it is capable of assembly into a functional binding domain when expressed as a portion of the chimeric antigen-binding protein.

### Vectors and Host Cells

The chimeric proteins of the present invention are preferably produced by recombinant DNA techniques. Thus, chimeric proteins are encoded by nucleic acid fusion constructs, which are cloned into expression vectors and expressed in appropriate host cells for the production of the chimeric protein. Such host cells may be prokaryotic or eukaryotic.

As reviewed in U.S. Patent No. 5,468,237, herein incorporated by reference in its entirety, many have had success with antibody expression and isolation using prokaryotic expression systems. In fact, U.S. Patent No. 5,648,237 discloses cloning vectors and methods for expressing antibodies and antibody fragments in *E. coli*, whereby the antibodies are secreted into and isolated from the periplasmic space of the microorganism. Also provided are methods for effecting covalent bond formation at the hinge region following antibody isolation.

The vector disclosed in U.S. Patent No. 5,648,237 is a dicistronic expression vector whereby the light chain and heavy chain fragments are each under the control of an inducible bacterial promoter. The redox environment in the bacterial periplasmic space apparently favors disulfide bond formation between light and heavy chains but not between the hinge cysteine residues. Others have had success in expressing heavy and light chains as a single polypeptide chain in bacteria. These disclosures are also incorporated by reference (Bird et al., 1988, *Science*, 242: 423-426; U.S. Patent Nos. 4,946,778 and 5,476,786; and Huston et al., 1988, *Proc. Natl. Acad. Sci. USA*, 1988, 85: 5879-5883).

-26-

Although U.S. Patent No. 5,648,237 indicates that Ig fusion proteins may be expressed in prokaryotic cells using the vectors described therein, depending on the immunoeffector moiety of the chimeric protein, i.e., the importance of glycosylation and proper protein secretion in maintaining binding function of the  
5 ligand, the chimeric proteins of the present invention may also be expressed using a eukaryotic, baculovirus or retrovirus expression system.

Vectors for designing recombinant antibody fusion proteins are well-known and available in the art. For instance, Challida-Eid et al. used an IgG3 expression vector to express their B7.1-IgG3 fusion protein (Coloma et al., 1992, Novel  
10 vectors for the expression of antibody molecules using variable regions generated by the polymerase chain reaction, *J. Immunol. Methods*, 152:89). Since the sequence of the Gp39 gene is known, one of ordinary skill in the art may readily amplify the required portion of the gene using PCR, while employing primers for such PCR which incorporate into the resulting nucleic acid convenient restriction  
15 sites for cloning. Such restriction sites depend on the sequence and length of the particular antibody used, and whether or not a linker region will also be incorporated.

Challida-Eid et al. expressed their B7.1-Ig fusion construct in non-secreting Sp2/0 cells. Since the chimeric proteins of the present invention contain an  
20 immunostimulatory ligand at the C-terminus, proteins may be purified by virtue of either the antigen binding domain or the immunoeffector portion. Techniques for preparing such columns and accomplishing the purification are also well-known in the art.

#### **Administration of the Chimeric Proteins**

25 The term "treatment" encompasses administration of compounds prophylactically to prevent or suppress an undesired condition, and therapeutic

-27-

administration to eliminate or reduce the extent or symptoms of the condition. Treatment according to the invention may be for a human or an animal so long as there are cells in said human or animal which express the target antigen. Treatment may be by systemic administration to the subject or by local application  
5 to an affected site.

The compositions of the present invention, i.e., compositions comprising a chimeric protein of the present invention, may be made into pharmaceutical compositions with appropriate pharmaceutically acceptable carriers or diluents. The chimeric proteins may be administered to a subject either singly or in  
10 combination with other chimeric proteins of the invention, or other known reagents commonly used in treatment regimens for the particular disease of interest. For instance, the proteins may also be used in therapy in conjunction with other anti-cancer or anti-viral drugs and biologicals, or in conjunction with other immune modulating therapy including bone marrow or lymphocyte transplants or  
15 medications.

As included within the scope of this invention, "acceptable" is defined as being compatible with other ingredients of the formulation and not injurious to the subject or other non-target cells. These carriers include those well known to practitioners in the art as suitable for oral, rectal, nasal, topical, buccal, sublingual,  
20 vaginal, or parenteral (including subcutaneous, intramuscular, intravenous, and intradermal) administration.

In the present case, it will be appreciated that the compounds according to the invention may also be used in the manufacture of pharmaceuticals for the treatment or prophylaxis of cancer and viral infections. Such formulations may  
25 be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring

-28-

only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

5 In the methods of the present invention, the mode of administration and dosage of protein chosen should be adequate to result in effective circulating levels of the chimeric protein. This will obviously depend on the type and stage of disease, location and number of diseased cells, level of antigen expression and type of antigen chosen (i.e., tumor-specific or tumor-associated), etc. However,  
10 dosages for intravenous administration will generally range from 0.001 mg/kg to about 10 mg/kg body weight of the patient, to be administered over several days or weeks by daily infusions depending on the patient's tolerance.

An "effective amount" of the composition is such as to produce the desired effect in a patient which can be monitored using several end-points known to those  
15 skilled in the art. For example, such effects could be monitored in terms of a therapeutic effect, e.g., alleviation of some symptom associated with the disease being treated, or further evidence suggesting enhanced immune response in the targeted area. These methods are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan.



**WHAT IS CLAIMED:**

1. A nucleic acid molecule comprising a nucleic acid encoding at least a heavy chain variable region binding domain of a disease antigen-specific antibody fused to a nucleic acid encoding at least a binding portion of an immunostimulatory ligand such that expression of said nucleic acid molecule yields a fusion protein having the antibody variable region domain at its amino terminus and the binding portion of the immunostimulatory ligand at its carboxyl terminus, wherein said immunostimulatory ligand is a CD40 ligand.
2. The nucleic acid molecule of Claim 1, further comprising a nucleic acid encoding at least one antibody constant region.
3. The nucleic acid molecule of Claim 1, further comprising a nucleic acid encoding a light chain antibody or antibody fragment fused with said nucleic acid encoding said antibody variable region.
4. The nucleic acid molecule of Claim 3, wherein said nucleic acid encoding said light chain antibody or antibody fragment is fused to said nucleic acid encoding said antibody variable region by a nucleic acid encoding a flexible peptide linker.
5. The nucleic acid molecule of Claim 1, wherein said disease antigen-specific antibody is specific for a tumor antigen.
6. The nucleic acid molecule of Claim 1, wherein said disease antigen-specific antibody is specific for a viral antigen.
7. The nucleic acid molecule of Claim 1, wherein said nucleic acid encoding said antibody variable region is fused to said nucleic acid encoding said binding portion of an immunostimulatory ligand by a nucleic acid encoding a linker peptide.
8. The nucleic acid of Claim 1, wherein said CD40 ligand is gp39.

-30-

9. A chimeric protein encoded by the nucleic acid molecule of Claim 1.

10. A chimeric protein comprising a variable region binding domain from a disease antigen-specific antibody at its amino terminus and an extracellular  
5 binding portion of an immunostimulatory ligand at its carboxyl terminus, wherein said immunostimulatory ligand is a CD40 ligand.

11. The chimeric protein of Claim 10, further comprising at least one antibody constant region.

12. The chimeric protein of Claim 10, further comprising a light chain  
10 antibody or antibody fragment.

13. The chimeric protein of Claim 12, wherein said light chain antibody or antibody fragment is fused to the amino terminal end of said protein by a flexible peptide linker.

14. The chimeric protein of Claim 10, wherein said disease antigen-  
15 specific antibody is specific for a tumor antigen.

15. The chimeric protein of Claim 10, wherein said disease antigen-specific antibody is specific for a viral antigen.

16. The chimeric protein of Claim 10, further comprising a linker peptide between said antibody variable region and said immunostimulatory ligand  
20 binding domain.

17. The chimeric protein of Claim 10, wherein said CD40 ligand is gp39.

18. A pharmaceutical composition comprising the chimeric protein of Claim 9.

25 19. A pharmaceutical composition comprising the chimeric protein of Claim 10.

-31-

20. A vector comprising the nucleic acid molecule of Claim 1.

21. A host cell comprising the nucleic acid molecule of Claim 1.

22. A method of making a chimeric protein comprising a variable region  
binding domain from a disease antigen-specific at its amino terminus and an  
5 extracellular binding portion of an immunostimulatory ligand at its carboxyl  
terminus comprising expressing the nucleic acid molecule of Claim 1 in a host cell  
and isolating the resulting chimeric protein.

23. A method of enhancing disease antigen-specific antibody responses  
in a subject who expresses said disease antigen comprising administering the  
10 chimeric protein of Claim 10, to said subject such that disease antigen-specific  
immune responses are enhanced.



24. A method of treating a disease in a patient in need of such treatment  
comprising administering the chimeric protein of Claim 10.

25. A kit comprising the nucleic acid molecule of Claim 1.



15 26. A kit comprising the chimeric protein of Claim 10.

1/2

Construct A (only the relevant heavy chain sequences shown below).

Construct B ( $F(ab')_2$ ; mAb variable chain sequences not shown).

Construct C (Fab; mAb variable chain sequences not shown).

Construct D (Fab w/ $C_{K/\lambda}/V_H$  linked; mAb heavy chain constant domain, mAb light chain variable domain and gp39 sequences not shown).

Construct E (Fv).



Fig. 1

Proposed TAA-specific mAb/gp39  
immunotherapeutic fusion proteins

2/2




Fig. 2

Anti-tumor immune response induction by a TAA  
specific mAb-gp39 chimeric protein

FOR UTILITY/DESIGN  
CIP/PCT NATIONAL/PLANT  
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL  
DECLARATIONS

RULE 63 (37 C.F.R. 1.63)  
DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PW  
FORM

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the **INVENTION ENTITLED** TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

the specification of which (CHECK applicable BOX(ES))  
X ☐ A. ☐ is attached hereto.  
BOX(ES) → B. ☐ was filed on \_\_\_\_\_ as U.S. Application No. \_\_\_\_\_ /  
→ C. ☒ was filed as PCT International Application No. PCT/ US99/27654 on 23 November 1999

and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application.

PRIOR FOREIGN APPLICATION(S) Number	Country	Day/MONTH/Year Filed	Date first Laid- open or Published	Date Patented or Granted	Priority NOT Claimed
--	---------	----------------------	---------------------------------------	-----------------------------	----------------------

**If more prior foreign applications, X box at bottom and continue on attached page.**

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S) Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status pending, abandoned, patented	Priority NOT Claimed
60/109,607	23 November 1998	pending	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Winthrop LLP, Intellectual Property Group, 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington, D.C. 20005-3918, telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	Kendrew H. Colton	30368	Roger R. Wise	31204	Anthony L. Miele	34393
G. Lloyd Knight	17698	G. Paul Edgell	24238	Michael R. Dzwonczyk	36787	Robert J. Walters	40862
Kevin E. Joyce	20508	Lynn E. Eccleston	35861	Jack S. Barufka	37087	Brian J. Beatus	38825
George M. Sirilla	18221	David A. Jakopin	32995	Adam R. Hess	41835	John Jobe	28429
Donald J. Bird	25323	Mark G. Paulson	30793	William P. Atkins	38821	Mark C. Pickering	36239
Dale S. Lazar	28872	Stephen C. Glazier	31361	Paul L. Sharer	36004	David H. Jaffer	32243
Glenn V. Perry	28458	Richard H. Zaitlen	27248	Robin L. Teskin	35030	Kenneth J. Woolcott	30984
Ramsey Stewart	38322	Christopher A. Dayton	35114				

(1) INVENTOR'S SIGNATURE:

Date: 7/19/99

Marco	Coccia		
First	Middle Initial	Family Name	
Residence	Camarillo	California, U.S.A.	U.S.A.
City	State/Foreign Country	Country of Citizenship	
Mailing Address	2242 Barbara Drive, Camarillo, California		
(include Zip Code)	93012		

(2) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence	City	State/Foreign Country	Country of Citizenship
Mailing Address	(include Zip Code)		

"X" box ☐ FOR ADDITIONAL INVENTORS, and proceed on the attached page to list each additional inventor.  
☐ See additional foreign priorities on attached page (incorporated herein by reference).

Atty. Dkt. No. P0280624  
(M#)

**Rule 56(a) & (b) = 37 C.F.R. 1.56(a) & (b)**  
**PATENT AND TRADEMARK CASES - RULES OF PRACTICE**  
**DUTY OF DISCLOSURE**

- (a) ...Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the [Patent and Trademark] Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability... (b) information is material to patentability when it is not cumulative and (1) It also establishes by itself, or in combination with other information, a prima facie case of unpatentability of a claim or (2) refutes, or is inconsistent with, a position the applicant takes in: (i) Opposing an argument of unpatentability relied on by the Office, or (ii) Asserting an argument of patentability

**PATENT LAWS 35 U.S.C.**

**§102. Conditions for patentability; novelty and loss of right to patent**

A person shall be entitled to a patent unless--

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months\* before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

**§103. Condition for patentability; non-obvious subject matter**

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. . . .
- (c) Subject matter developed by another person, which qualified as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

---

\* Six months for Design Applications (35 U.S.C. 172).